FDA Approves Gene-Editing Therapies for Sickle Cell Disease
The US Food and Drug Administration (FDA) announced last week that it has approved Casgevy and Lyfgenia, two groundbreaking, gene-editing treatments for sickle cell disease (SCD) in patients 12 years and older. Sickle cell disease is a group of inherited blood disorders which affects around 100,000 people in the US.
